Subjects | 44 | 41 | 48 | 45 |
Costs EUR | | | | |
Trial medications | 986 | 227 | 0 | 1213 |
Initial hospital stay, nonsurgical | 7155±9991 | 11 164±27 892 | 11 687±27 133 | 5701±4604 |
Initial hospital stay, surgical | 1953±8874 | 5401±17 247 | 1113±4159 | 234±1098 |
Subsequent admissions | 511±2026 | 1065±6820 | 682±2865 | 102±682 |
Total costs | 10 605±15 413 | 17 856±34 861 | 13 483±28 798 | 7248±4922 |
Life-years gained | 0.988±0.081 | 0.923±0.228 | 0.969±0.147 | 0.969±0.153 |
Cost-effectiveness of placebo versus trial interventions | | | | |
ICER | t-PA dominant | Placebo dominant | NA | EUR 1.6 billion |
Probability placebo cost-effective | 0.24 | 0.81 | NA | 0.04 |